Microcap Ledger

Tickers · $SINT

Sintx Technologies, Inc. $SINT

By Microcap Ledger desk · CIK 0001269026

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Surgical & Medical Instruments & Apparatus
Headquarters
Salt Lake City, UT
Fiscal year end
December 31
Shares outstanding
6,664,534 [10-Q 2026-08-11]
as of 2026-08-05

Sources: [10-K 2026-03-20]

What the company doesAI summary of filing

Sintx Technologies is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials and devices for medical and industrial applications. The company generates revenue from biomedical products, including spinal implants that have been implanted in humans since 2008 and the recently FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System, as well as from manufacturing silicon nitride parts for aerospace and electrical customers. Sintx is also developing antipathogenic products incorporating its silicon nitride material into face masks, filters, and wound care devices. The company is pre-revenue or early-stage for most of its development programs, though it has achieved regulatory clearances for certain biomedical products and generates revenue from existing commercial products and manufacturing for original equipment manufacturers. [10-K 2026-03-20]

Segments: Biomedical implants (spinal fusion, foot and ankle, joint replacements), Antipathogenic products (face masks, filters, wound care), Industrial components (aerospace, electrical)

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$832.0K−$5.53M −$5.26M$3.59M[10-Q 2026-08-11]
FY ended Dec 2025$1.02M−$10.36M −$8.57M$4.14M[10-K 2026-03-20]
FY ended Dec 2024$2.89M−$11.02M −$8.64M$3.60M[10-K 2026-03-20]
Quarterly cash burn
−$2.63M
Cash runway Estimate
~4.1 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-061,342,853[10-Q 2024-11-12]
2025-03-112,515,179[10-K 2025-03-19]
2025-05-132,508,706[10-Q 2025-05-15]
2025-08-082,758,865[10-Q 2025-08-14]
2025-11-073,851,956[10-Q 2025-11-12]
2026-03-134,121,727[10-K 2026-03-20]
2026-05-084,319,279[10-Q 2026-05-15]
2026-08-056,664,534[10-Q 2026-08-11]
Shelf registration
S-3 filed 2026-08-13; declared effective 2026-08-18 [S-3 2026-08-13]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-05-27. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

DateEventDetailsDeadlineFiling
2026-05-278-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2026-05-27]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-04-13Elmore Robert Ryangrant4,910$2.88[4 2026-04-14]
2026-03-02Lyons Christopher Michaelbuy7,534$2.90[4 2026-03-10]
2026-02-25Lyons Christopher Michaelbuy758$2.96[4 2026-03-10]
2026-02-23Moyes Jay Mbuy1,000$2.91[4 2026-02-25]
2026-02-18Anderson Mark Lewisbuy3,000$3.02[4 2026-02-19]

Catalysts and calendar

Facts as of . Small caps move fast; check the latest filings.